Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Monte Rosa Therapeutics, Inc. - Common Stock (NQ:GLUE)

18.92 +0.64 (+3.50%)
Streaming Delayed Price Updated: 2:32 PM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Monte Rosa Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results
Conference call and webcast to be held at 8 a.m. ET on January 7, 2026 
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results
Conference call and webcast to be held at 8 a.m. ET on December 16, 2025 
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader Medicines
Monte Rosa’s AI/ML-powered insights dramatically increase targetable protein space for molecular glue degraders, unlocking new opportunities to address previously undruggable therapeutic targets 
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.